We are Sorry, This Page doesn't Exist

Former Juno Therapeutics Inc. executives Hans Bishop and Steve Harr have co-founded a new biotech, Sana Biotechnology Inc., less than a year after leading Juno through a $9 billion acquisition by Celgene Corp......»»

The acquisition of Kite Pharmaceuticals by Gilead and Juno Therapeutics by Celgene may lead to more acquisitions of CAR-T gene therapy companiesRelated Stocks: GILD, NVS, CELG, MBIO, CYAD, CLLS, PFE, BLCM,.....»»

Vertex Pharmaceuticals Inc. said Tuesday it plans to pay $1.1 billion to Crispr Therapeutics AG as part of a deal to test an experimental gene-editing therapy for sickle cell disease and transfusion-dependent beta-tha.....»»

With blockbuster immunology treatments Enbrel (via $16 billion acquisition of Immunex in 2009) and Otezla (added in 2013 via $13 billion deal) already in its bag, Amgen Inc (NASDAQ: AMGN) read more.....»»

Design Therapeutics Inc. has set terms for its initial public offering, .....»»

Amgen Inc. announced Thursday an agreement to buy biotechnology company Five Prime Therapeutics Inc......»»

Bristol Myers Squibb Co. said Thursday it had a net loss of $10.027.....»»

Horizon Therapeutics Plc said Monday it has agreed to acquire Viela Bio Inc. for $53 a share in cash, or an equity value of about $3.05 billion. The deal is expected.....»»

In the wake of its potential $4 billion deal with Bayer, the firm is expanding its leadership team......»»

Eli Lilly will pay $22.50 per share for Prevail, as well as an additional $4 per share that hing.....»»

ADC Therapeutics S.A. set terms of its initial public offering, as the Switzerland-based biotechnology company focused on cancer treatments looks to raise up to $185.3 million. ADC is offering 10,295,000 shares in the IPO, which is.....»»

Fate Therapeutics Inc (NASDAQ: FATE) shares are trading higher on Friday, after a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. read more.....»»

Genentech Inc. will pay $30 million upfront — and potentially $1.7 billion overall based on milestones — to work on a set of potential cancer immunotherapies with a British company. For Bicycle Therapeutics plc of Cambridge, England, and Lexington.....»»

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States......»»

Akero, Dermira, Global Blood Therapeutics and Moderna all have drugs that could hit $1 billion in salesRelated Stocks: AKRO, DERM, RHHBY, GBT, NVS, MRNA, MORF,.....»»

Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment......»»

Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics clearing the way for the Swiss drugmaker's push into treating rare diseases including hemophilia A......»»

Astellas Pharma Inc.’s $3 billion acquisition of Audentes Therapeutics is a strong indicator that the pharmaceutical industry’s march into gene therapy development isn’t going to slow down in 2020......»»

Bristol-Myers Squibb Co. on Wednesday said it completed its $74 billion acquisition of Celgene Corp. , nearly a year after announcing the controversial de.....»»